

# Michael J Morris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1158667/publications.pdf>

Version: 2024-02-01

135  
papers

18,377  
citations

26626

56  
h-index

12272

133  
g-index

139  
all docs

139  
docs citations

139  
times ranked

18214  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	28.9	2,660
2	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 1148-1159.	1.6	1,960
3	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. <i>Cell</i> , 2014, 159, 176-187.	28.9	1,184
4	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	1.6	1,089
5	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1&sup2; study. <i>Lancet</i> , The, 2010, 375, 1437-1446.	13.7	972
6	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 591-597.	1.6	584
7	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	1.9	488
8	Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401. <i>Journal of Clinical Oncology</i> , 2012, 30, 1534-1540.	1.6	436
9	Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 671-677.	1.6	410
10	Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1496-1501.	1.6	396
11	Phase II Study of Lutetium-177&sup2;-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5182-5191.	7.0	370
12	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1652-1659.	1.6	332
13	Germline <i>BRCA</i> Mutations Denote a Clinicopathologic Subset of Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2115-2121.	7.0	263
14	Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance). <i>Journal of Clinical Oncology</i> , 2014, 32, 1143-1150.	1.6	217
15	Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1307-1316.	10.7	205
16	Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. <i>Urology</i> , 2002, 59, 913-918.	1.0	203
17	Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7421-7428.	7.0	203
18	End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice. <i>Journal of Clinical Oncology</i> , 2011, 29, 3695-3704.	1.6	202

#	ARTICLE	IF	CITATIONS
19	Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1775-1782.	7.0	198
20	Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 537-556.	1.6	189
21	Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. <i>Clinical Cancer Research</i> , 2021, 27, 3674-3682.	7.0	179
22	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5277-5285.	7.0	163
23	Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 519-524.	1.6	162
24	Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1384-1393.	6.4	160
25	A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index. <i>European Urology</i> , 2012, 62, 78-84.	1.9	158
26	Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 6093-6099.	7.0	130
27	89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2093-2105.	6.4	130
28	HER2 profiling and targeting in prostate carcinoma. <i>Cancer</i> , 2002, 94, 980-986.	4.1	128
29	Prostate Cancer Clinical Trial End Points: RECISTing a Step Backwards. <i>Clinical Cancer Research</i> , 2005, 11, 5223-5232.	7.0	126
30	Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 3210-3216.	7.0	122
31	Pilot Trial of Unlabeled and Indium-111 Labeled Anti-Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 7454-7461.	7.0	120
32	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. <i>Journal of Clinical Oncology</i> , 2015, 33, 1356-1363.	1.6	120
33	Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2008, 49, 2031-2041.	5.0	118
34	When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1534-1541.	6.3	118
35	First-in-Human Imaging with <sup>89</sup> Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1858-1864.	5.0	116
36	Pharmacokinetic Assessment of the Uptake of <sup>18</sup> F-Fluoro-5 $\alpha$ -Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 183-192.	5.0	113

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 675-681.	1.6	102
38	Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2436-2442.	1.6	92
39	Bone Metastases in Castration-Resistant Prostate Cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival. <i>Radiology</i> , 2014, 271, 220-229.	7.3	88
40	Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases. <i>Clinical Cancer Research</i> , 2007, 13, 5816-5824.	7.0	84
41	Validation and clinical utility of prostate cancer biomarkers. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 225-234.	27.6	83
42	Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using <sup>111</sup> In-J591: Lesion Detectability and Dosimetric Projections for <sup>90</sup> Y Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1066-1074.	5.0	76
43	Targeting the androgen receptor in prostate and breast cancer: several new agents in development. <i>Endocrine-Related Cancer</i> , 2015, 22, R87-R106.	3.1	76
44	Androgen deprivation and thromboembolic events in men with prostate cancer. <i>Cancer</i> , 2012, 118, 3397-3406.	4.1	74
45	Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 2707-2713.	7.0	73
46	<sup>11</sup> C-acetate PET imaging in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 181-184.	6.4	73
47	Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer. <i>European Urology</i> , 2009, 56, 237-244.	1.9	73
48	Brain Metastases from Prostate Cancer: An 11-Year Analysis in the MRI Era with Emphasis on Imaging Characteristics, Incidence, and Prognosis. <i>Journal of Neuroimaging</i> , 2014, 24, 161-166.	2.0	72
49	Radium-223 mechanism of action: implications for use in treatment combinations. <i>Nature Reviews Urology</i> , 2019, 16, 745-756.	3.8	71
50	Methylphenidate for fatigue in ambulatory men with prostate cancer. <i>Cancer</i> , 2010, 116, 5102-5110.	4.1	70
51	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6802-6811.	7.0	69
52	Augmenting advance care planning in poor prognosis cancer with a video decision aid. <i>Cancer</i> , 2012, 118, 4331-4338.	4.1	66
53	A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1921-1930.	4.2	64
54	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. <i>EJNMMI Research</i> , 2015, 5, 28.	2.5	63

#	ARTICLE	IF	CITATIONS
55	Repeatability of Quantitative <sup>18</sup> F-NaF PET: A Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1872-1879.	5.0	62
56	Imaging therapeutic response in human bone marrow using rapid whole-body MRI. <i>Magnetic Resonance in Medicine</i> , 2004, 52, 1234-1238.	3.0	61
57	Radiation Safety Considerations for the Use of <sup>223</sup> RaCl <sub>2</sub> DE in Men with Castration-resistant Prostate Cancer. <i>Health Physics</i> , 2014, 106, 494-504.	0.5	59
58	Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 658-667.	4.3	57
59	A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 581-588.	1.6	57
60	A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. <i>Urology</i> , 2017, 102, 164-172.	1.0	52
61	Quantitative Assessment of Early [ <sup>18</sup> F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone. <i>Journal of Clinical Oncology</i> , 2017, 35, 2829-2837.	1.6	52
62	Developing imaging strategies for castration resistant prostate cancer. <i>Acta Oncologica</i> , 2011, 50, 39-48.	1.8	48
63	Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1727-1732.	5.0	46
64	Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)1A.J.A. and R.K. contributed equally to this work.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1308-1316.	1.6	46
65	Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. <i>Clinical Cancer Research</i> , 2016, 22, 4890-4900.	7.0	46
66	Computer-aided quantitative bone scan assessment of prostate cancer treatment response. <i>Nuclear Medicine Communications</i> , 2012, 33, 384-394.	1.1	45
67	Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 41-45.	5.0	45
68	Expression of prostate-specific membrane antigen in renal cortical tumors. <i>Modern Pathology</i> , 2008, 21, 727-732.	5.5	42
69	Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 880-887.	7.0	42
70	A Phase II Trial of Bortezomib and Prednisone for Castration Resistant Metastatic Prostate Cancer. <i>Journal of Urology</i> , 2007, 178, 2378-2384.	0.4	40
71	Germline <i>BRCA</i> mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. <i>BJU International</i> , 2012, 109, 713-719.	2.5	40
72	High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. <i>Cancer</i> , 2004, 100, 1868-1875.	4.1	39

#	ARTICLE	IF	CITATIONS
73	Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 530.e15-530.e21.	1.6	38
74	Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. <i>EJNMMI Research</i> , 2016, 6, 23.	2.5	37
75	Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. <i>Cancer</i> , 2003, 98, 1842-1848.	4.1	35
76	Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?. <i>Seminars in Oncology</i> , 2013, 40, 375-392.	2.2	34
77	Clinical Approaches to Osseous Metastases in Prostate Cancer. <i>Oncologist</i> , 2003, 8, 161-173.	3.7	32
78	Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). <i>Cancer</i> , 2015, 121, 1025-1031.	4.1	32
79	Phase II Trial of Docetaxel With Rapid Androgen Cycling for Progressive Noncastrate Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2959-2965.	1.6	31
80	A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1865-1871.	5.0	31
81	A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1089-1097.	2.3	30
82	Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e305-e309.	1.9	30
83	Prevalence of Pain and Analgesic Use in Men With Metastatic Prostate Cancer Using a Patient-Reported Outcome Measure. <i>Journal of Oncology Practice</i> , 2013, 9, 223-229.	2.5	29
84	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. <i>Clinical Cancer Research</i> , 2022, 28, 318-326.	7.0	28
85	Therapeutic Strategies for Bone Metastases and Their Clinical Sequelae in Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2012, 13, 174-188.	3.0	27
86	Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. <i>Cancer</i> , 2015, 121, 3853-3861.	4.1	27
87	Safety and Biologic Activity of Intravenous BCL-2 Antisense Oligonucleotide (G3139) and Taxane Chemotherapy in Patients With Advanced Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2005, 13, 6-13.	1.2	24
88	Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 7414-7421.	7.0	23
89	Repetitively dosed docetaxel and <sup>153</sup> samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2013, 119, 3186-3194.	4.1	23
90	A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4746-4756.	7.0	22

#	ARTICLE	IF	CITATIONS
91	Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 51-57.	1.9	21
92	Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 763-771.	2.3	21
93	Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3774-3781.	7.0	21
94	Assessing outcomes in prostate cancer clinical trials. <i>Cancer</i> , 2008, 113, 966-974.	4.1	19
95	The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer. <i>Cancer</i> , 2013, 119, 3636-3643.	4.1	17
96	Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	17
97	Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-axis Imaging. <i>Journal of Nuclear Medicine</i> , 2016, 57, 73S-78S.	5.0	16
98	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	2.3	16
99	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, 131-141.	3.8	16
100	Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. <i>Surgical Oncology</i> , 2002, 11, 13-23.	1.6	15
101	Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 522-530.	3.9	15
102	Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 419-426.	6.3	15
103	Harnessing Naturally Occurring Tumor Immunity: A Clinical Vaccine Trial in Prostate Cancer. <i>PLoS ONE</i> , 2010, 5, e12367.	2.5	14
104	Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 3S-5S.	5.0	14
105	Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 309-316.	3.9	14
106	A Comparative Review of Autologous Conditioned Serum and Autologous Protein Solution for Treatment of Osteoarthritis in Horses. <i>Frontiers in Veterinary Science</i> , 2021, 8, 602978.	2.2	14
107	A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). <i>EBioMedicine</i> , 2015, 2, 1814-1820.	6.1	13
108	Men's Eating and Living ( MEAL ) study ( CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. <i>BJU International</i> , 2018, 121, 534-539.	2.5	13



#	ARTICLE	IF	CITATIONS
109	Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 553-561.	6.3	12
110	Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3011-3014.	1.6	12
111	Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine. <i>Urology</i> , 2002, 60, 1111.	1.0	11
112	Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 347-352.	2.0	11
113	Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). <i>European Urology Oncology</i> , 2021, 4, 543-552.	5.4	11
114	Fully automated synthesis of [ <sup>18</sup> F]fluoro- $\alpha$ -dihydrotestosterone ([ <sup>18</sup> F]FDHT) using the FlexLab module. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 424-428.	1.0	10
115	Seek and Find: Current Prospective Evidence for Prostate-specific Membrane Antigen Imaging to Detect Recurrent Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 267-278.	3.1	10
116	Androgen deprivation for minimal metastatic disease: Threshold for achieving undetectable prostate-specific antigen. <i>Urology</i> , 2005, 65, 947-952.	1.0	9
117	Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 66-73.	3.9	9
118	A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 13247-13263.	2.0	8
119	Castration Resistant, Taxane Naïve Metastatic Prostate Cancer: Current Clinical Approaches and Future Directions. <i>Journal of Urology</i> , 2007, 178, S30-5.	0.4	6
120	Failure of ELM-PC 5: An Ineffective Drug or an Unfit End Point?. <i>Journal of Clinical Oncology</i> , 2015, 33, 679-681.	1.6	6
121	Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223. <i>Prostate</i> , 2017, 77, 245-254.	2.3	6
122	Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 126-132.	3.9	6
123	Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 21-31.	4.4	4
124	Serological evaluation of ovarian steroids of red-rumped agouti ( <i>Dasyprocta leporina</i> ) during the estrous cycle phases. <i>Animal Reproduction Science</i> , 2016, 175, 27-32.	1.5	4
125	Serosurvey for Infectious Agents Associated with Subfertility and Abortion in Dairy Cattle in Trinidad and Tobago, West Indies. <i>Veterinary Sciences</i> , 2018, 5, 51.	1.7	4
126	A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 447-456.	1.9	3



#	ARTICLE	IF	CITATIONS
127	Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 69-79.	1.9	2
128	Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 536-537.	4.3	1
129	Reply to B. Rini et al and S. Buti et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1859-1860.	1.6	1
130	Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, , .	1.9	1
131	Systemic therapy. , 0, , 93-101.		0
132	Reply to Tomasz Drewna and Piotr Chłosta's Letter to the Editor re: Michael J. Morris, Daisy Huang, William K. Kelly, et al. Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate. <i>Eur Urol</i> 2009;56:237-44. <i>European Urology</i> , 2010, 57, e20.	1.9	0
133	A Case Report of Putative Autoimmunity to Prostate Cancer After Immune-Mediated Rejection of Melanoma Through a Shared Tumor Antigen. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 126-129.	1.9	0
134	Reply to K. Lu. <i>Journal of Clinical Oncology</i> , 2015, 33, 3222-3223.	1.6	0
135	Mitral Kissing Vegetation and Acquired Aortic Valve Stenosis Secondary to Infectious Endocarditis in a Goat with Suppurative Mastitis. <i>Veterinary Sciences</i> , 2018, 5, 64.	1.7	0